Stoke Therapeutics News - STOK

Company Name	Stock Ticker Symbol	Market	Type
Stoke Therapeutics Inc	STOK	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.33	2.82%	12.02	16:00:05

Open Price	Low Price	High Price	Close Price	Prev Close
12.00	11.585	12.6037	12.02	11.69

more quote information »

Recent News

Date	Time	Source	Heading
4/29/2024	08:00	BW	Stoke Therapeutics Appoints Thomas Leggett as Chief..
4/17/2024	08:00	BW	Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial..
4/04/2024	16:30	BW	Stoke Therapeutics to Present at the 23rd Annual Needham..
3/27/2024	23:40	BW	Stoke Therapeutics Announces Pricing of Upsized $125 Million..
3/26/2024	16:07	BW	Stoke Therapeutics Announces Proposed Public Offering
3/25/2024	16:01	BW	Stoke Therapeutics Reports Fourth Quarter and Full Year 2023..
3/05/2024	16:21	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
3/01/2024	16:28	EDGAR2	Form 144 - Report of proposed sale of securities
2/26/2024	10:38	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/26/2024	10:36	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
2/14/2024	09:20	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/05/2024	16:32	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/01/2024	16:49	EDGAR2	Form 144 - Report of proposed sale of securities
1/17/2024	16:30	BW	Stoke Therapeutics Announces Inducement Grants Under Nasdaq..
1/08/2024	08:09	EDGAR2	Form 8-K - Current report
1/08/2024	08:00	BW	Stoke Therapeutics Highlights Strategic Priorities and..
1/04/2024	16:38	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/04/2024	16:30	BW	Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan..
1/02/2024	16:29	EDGAR2	Form 144 - Report of proposed sale of securities
12/14/2023	16:05	EDGAR2	Form 8-K - Current report
12/05/2023	16:18	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/05/2023	16:17	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/05/2023	16:09	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/05/2023	16:08	EDGAR2	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
12/01/2023	09:04	EDGAR2	Form 8-K - Current report
12/01/2023	09:00	BW	Stoke Therapeutics Presents Data From Multiple Studies of..
11/21/2023	08:00	BW	Stoke Therapeutics to Present Data from the Company’s Dravet..
11/17/2023	16:37	EDGAR2	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/09/2023	16:28	EDGAR2	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/07/2023	16:05	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/2023	07:05	EDGAR2	Form 8-K - Current report
11/07/2023	07:00	BW	Stoke Therapeutics Reports Third Quarter Financial Results..
11/06/2023	16:55	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
11/02/2023	09:01	EDGAR2	Form SC TO-I - Tender offer statement by Issuer
10/26/2023	17:00	EDGAR2	Form 8-K - Current report
10/17/2023	16:30	BW	Stoke Therapeutics Announces Inducement Grants Under Nasdaq..
9/28/2023	16:05	EDGAR2	Form DEF 14A - Other definitive proxy statements
9/21/2023	08:00	BW	Stoke Therapeutics to Participate in the 2023 Cantor Global..
9/20/2023	16:37	EDGAR2	Form 8-K - Current report
9/20/2023	16:30	BW	Stoke Therapeutics Appoints Ian Smith to its Board of..
9/18/2023	16:05	EDGAR2	Form PRE 14A - Other preliminary proxy statements
9/05/2023	07:00	BW	Stoke Therapeutics Presents Data Related to the Ongoing..
8/07/2023	16:06	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/07/2023	07:05	EDGAR2	Form 8-K - Current report
8/07/2023	07:00	BW	Stoke Therapeutics Reports Second Quarter Financial Results..
8/02/2023	08:00	BW	Stoke Therapeutics to Present at the Canaccord Genuity 43rd..
7/25/2023	07:05	EDGAR2	Form 8-K - Current report
7/25/2023	07:00	BW	Stoke Therapeutics Announces Positive New Safety & Efficacy..
7/21/2023	07:30	BW	Stoke Therapeutics to Host Webinar to Present New Data from..
7/06/2023	17:20	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..